Literature DB >> 16998235

Mycophenolate mofetil for interstitial lung disease in scleroderma.

S C Plastiras, P G Vlachoyiannopoulos, G E Tzelepis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16998235     DOI： 10.1093/rheumatology/kel335

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  7 in total

Review 1.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

2.  Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?

Authors:  Joanna Busquets; Francesco Del Galdo; Eugene Y Kissin; Sergio A Jimenez
Journal:  Rheumatology (Oxford)       Date:  2010-03-04       Impact factor: 7.580

3.  Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab.

Authors:  Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

4.  Medical management of retroperitoneal fibrosis.

Authors:  Paul J Scheel; Stephen M Sozio; Nancy Feeley
Journal:  Trans Am Clin Climatol Assoc       Date:  2012

5.  Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis.

Authors:  Argyris Tzouvelekis; Nikolaos Galanopoulos; Evangelos Bouros; George Kolios; George Zacharis; Paschalis Ntolios; Andreas Koulelidis; Anastasia Oikonomou; Demosthenes Bouros
Journal:  Pulm Med       Date:  2012-05-10

Review 6.  Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.

Authors:  Mohammed A Omair; Abdulaziz Alahmadi; Sindhu R Johnson
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

7.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.